Congratulations to Dr. Wang Yongjun, a trailblazing clinical scientist from the Chinese mainland, for winning the prestigious William M. Feinberg Award for Excellence in Clinical Stroke at the 2025 International Stroke Conference (ISC) in Los Angeles!
This is the first time an Asian scientist has clinched this top honor in the award's 34-year history, marking a significant milestone in stroke research.
As the president of Beijing Tiantan Hospital and the Chinese Stroke Association, Dr. Wang and his team have revolutionized stroke treatment over the past three decades. They've introduced 12 key pieces of evidence that have reshaped clinical guidelines worldwide.
Dr. Wang emphasized the impact of their work: \"Our team's evidence on intravenous thrombolytic therapy for ischemic stroke has been a game-changer.\" His innovative use of imaging and AI technologies extended the thrombolysis window from 4.5 to 24 hours, allowing 90% of acute ischemic stroke patients to receive life-saving treatment and reducing disability rates by 8.8% without increasing hemorrhage risks.
Moreover, their development of a combined aspirin and clopidogrel treatment has halved stroke recurrence rates globally, benefiting nearly one million stroke patients in China alone.
Dr. Wang also highlighted the power of collaboration, with over 2,400 hospitals in China participating in their extensive clinical research network. This teamwork has led to over 50 national clinical studies in the past decade, providing Chinese solutions to international stroke prevention and treatment challenges.
The ISC, attended by around 4,000 professionals, showcased the latest advances in stroke prevention, treatment, and rehabilitation, making Dr. Wang's achievement a shining highlight of the event.
Let's celebrate Dr. Wang Yongjun's incredible contributions to science and medicine!
NewspaperAmigo – Your Global News Buddy 
